Molecular profiling of non-small cell lung cancer

Marika L. Forsythe, Akram Alwithenani, Drew Bethune, Mathieu Castonguay, Arik Drucker, Gordon Flowerdew, Daniel French, John Fris, Wenda Greer, Harry Henteleff, Mary MacNeil, Paola Marignani, Wojciech Morzycki, Madelaine Plourde, Stephanie Snow, Zhaolin Xu

Résultat de recherche: Articleexamen par les pairs

21 Citations (Scopus)

Résumé

Lung cancer is generally treated with conventional therapies, including chemotherapy and radiation. These methods, however, are not specific to cancer cells and instead attack every cell present, including normal cells. Personalized therapies provide more efficient treatment options as they target the individual's genetic makeup. The goal of this study was to identify the frequency of causal genetic mutations across a variety of lung cancer subtypes in the earlier stages. 833 samples of non-small cell lung cancer from 799 patients who received resection of their lung cancer, were selected for molecular analysis of six known mutations, including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK. A SNaPshot assay was used for point mutations and fragment analysis searched for insertions and deletions. ALK was evaluated by IHC +/- FISH. Statistical analysis was performed to determine correlations between molecular and clinical/pathological patient data. None of the tested variants were identified in most (66.15%) of cases. The observed frequencies among the total samples vs. only the adenocarcinoma cases were notable different, with the highest frequency being the KRAS mutation (24.49% vs. 35.55%), followed by EGFR (6.96% vs. 10.23%), PIK3CA (1.20% vs. 0.9%), BRAF (1.08% vs. 1.62%), ALK (0.12% vs. 0.18%), while the lowest was the HER2 mutation (0% for both). The statistical analysis yielded correlations between presence of a mutation with gender, cancer type, vascular invasion and smoking history. The outcome of this study will provide data that helps stratify patient prognosis and supports development of more precise treatments, resulting in improved outcomes for future lung cancer patients.

Langue d'origineEnglish
Numéro d'articlee0236580
JournalPLoS One
Volume15
Numéro de publication8 August 2020
DOI
Statut de publicationPublished - août 2020

Note bibliographique

Funding Information:
The study was partially supported by Roche Canada, Pfizer Canada and Boehringer Ingelheim Canada. The funders had no role instudy design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
© 2020 Forsythe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ASJC Scopus Subject Areas

  • General

Empreinte numérique

Plonger dans les sujets de recherche 'Molecular profiling of non-small cell lung cancer'. Ensemble, ils forment une empreinte numérique unique.

Citer